CA2826725C — High concentration olopatadine ophthalmic composition
Assigned to Novartis AG · Expires 2016-11-01 · 10y expired
What this patent protects
The invention relates to an ophthalmic composition for treatment of ocular itching and/or ocular redness associated with ocular allergic conjunctivitis, the composition comprising: at least 0.67 w/v % olopatadine. In one aspect, the invention is a use of a high concentration of o…
USPTO Abstract
The invention relates to an ophthalmic composition for treatment of ocular itching and/or ocular redness associated with ocular allergic conjunctivitis, the composition comprising: at least 0.67 w/v % olopatadine. In one aspect, the invention is a use of a high concentration of olopatadine for the treatment of ocular itching and/or ocular redness associated with ocular allergic conjunctivitis. In another aspect, the invention is a formulation wherein a high concentration of olopatadine is solubilized. In one embodiment, the formulation comprises a .beta.- or .gamma.-cyclodextrin, and a lactam polymer and a polyether.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.